Iloprost inhalation solution for the treatment of pulmonary arterial hypertension

被引:21
作者
Hsu, HH [1 ]
Rubin, LJ [1 ]
机构
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92037 USA
关键词
iloprost; prostacyclin analogues; pulmonary arterial hypertension;
D O I
10.1517/14656566.6.11.1921
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pulmonary arterial hypertension (PAH) is a condition that is characterised by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death. A variety of disturbances in pulmonary vascular enclothelial and smooth muscle function are present in PAH, including reduced production of vasodilator and anti proliferative substances, such as nitric oxide and prostacyclin, and an overproduction of mitogens, such as endothelin. As a result of these observations, therapies have been developed for PAH that specifically target these pathogenic processes, including prostacyclin analogues and endothelin receptor antagonists. This article reviews iloprost inhalation solution, the most recently approved form of prostacyclin therapy that is delivered directly to the lungs by inhalation.
引用
收藏
页码:1921 / 1930
页数:10
相关论文
共 68 条
[1]   Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise [J].
Blumberg, FC ;
Riegger, GAJ ;
Pfeifer, M .
CHEST, 2002, 121 (05) :1566-1571
[2]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[3]   Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery [J].
Clapp, LH ;
Finney, P ;
Turcato, S ;
Tran, S ;
Rubin, LJ ;
Tinker, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (02) :194-201
[4]  
COWLEY AJ, 1985, THROMB HAEMOSTASIS, V53, P90
[5]   Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: Role of thromboxane A(2) [J].
Cuiper, LL ;
Price, PV ;
Christman, BW .
JOURNAL OF APPLIED PHYSIOLOGY, 1996, 80 (01) :191-197
[6]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[7]   Hoprost in persistent pulmonary hypertension of the newborn [J].
Ehlen, M ;
Wiebe, B .
CARDIOLOGY IN THE YOUNG, 2003, 13 (04) :361-363
[8]   Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost [J].
Fruhwald, FM ;
Kjellström, B ;
Perthold, WF ;
Watzinger, N ;
Maier, R ;
Grandjean, PA ;
Klein, W .
CHEST, 2003, 124 (01) :351-359
[9]   Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension [J].
Gessler, T ;
Schmehl, T ;
Hoeper, MM ;
Rose, F ;
Ghofrani, HA ;
Olschewski, H ;
Grimminger, F ;
Seeger, W .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (01) :14-19
[10]   Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension [J].
Ghofrani, HA ;
Wiedemann, R ;
Rose, F ;
Olschewski, H ;
Schermuly, RT ;
Weissmann, N ;
Seeger, W ;
Grimminger, F .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (07) :515-522